Stocks and Finance

Affymax

Affymax 3/27/2012

14:17 : Affymax ([[AFFY]] +10.9%) shares resume trading, popping more than 10% ... - Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after confirming the FDA cleared the company's peginesatide anemia treatment for patients on dialysis for chronic kidney disease. The drug will be AFFY's first marketed ...
Source : seekingalpha-com

Affymax 3/26/2012

03:42 : Affymax, MAP drug approvals would net royalty bounty for Nektar - Nektar Therapeutics Inc. could help its bottom line — and move closer toward paying off debt — by doing almost nothing Monday and Tuesday. San Francisco-based Nektar (NASDAQ: NKTR) is in line for royalty payments if the Food ...
Source : bizjournals-com

Affymax 2/27/2012

10:39 : Affymax gets $5M milestone payment from Takeda - Affymax said it is expected to received a $5 million development milestone payment from Takeda Pharmaceutical. The Palo Alto-based biopharmaceutical company said the payment comes as a result of a global agreement between the two companies ...
Source : bizjournals-com
09:28 : Affymax secures $5M milestone payment from Takeda - Affymax Inc. said Monday it is expected to received a $5 million development milestone payment from Takeda Pharmaceutical Co. The Palo Alto-based biopharmaceutical company (NASDAQ:AFFY) said the payment comes as a result of a global agreement ...
Source : bizjournals-com

Affymax 1/13/2012

13:38 : Affymax ([[AFFY]] -0.3%) CEO John Orwin says the days of biotech companies - Affymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price bid up on potential is over, as investors wait it out to see if firms hash out issues with reimbursements, regulatory hurdles, and safety concerns. ...
Source : seekingalpha-com

Affymax 12/8/2011

07:45 : Shares of Affymax (AFFY) are now up 30% premarket after being halted earlie - Shares of Affymax (AFFY) are now up 30% premarket after being halted earlier. All the excitement stems from the firm landing FDA backing for its peginesatide anemia drug. Post your comment!
Source : seekingalpha-com

Affymax 12/7/2011

18:49 : Affymax ([[AFFY]] +8.9%) wins backing from an FDA advisory panel for its ... - Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's ...
Source : seekingalpha-com
17:19 : FDA panel backs Affymax anemia drug for dialysis patients - A federal advisory panel Wednesday approved Affymax Inc.’s once-a-month anemia drug for kidney dialysis patients. The 17-member Food and Drug Administration panel of outside experts recommended that the agency approve peginesatide from ...
Source : bizjournals-com

Affymax 12/5/2011

12:15 : Affymax rallies ahead of FDA meeting - BOSTON (MarketWatch) -- Shares of Affymax Inc. rallied 20% to $6.28 on Monday ahead of an advisory panel meeting of the U.S. Food and Drug Administration slated for Wednesday that will consider whether to recommend its anemia-fighting drug ...
Source : marketwatch-com
actualidad Affymax -


Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Biotechnology

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts